

ASX Announcement

21st December 2023

RIGHTS ISSUE CLEANSING NOTICE

Genetic Signatures Limited (ASX: GSS, the “Company”) gives notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth) (“Corporations Act”). On 21 December 2023, the Company announced a capital raising comprising:

- (a) placement of fully paid ordinary shares (“New Shares”) to sophisticated and institutional investors (“Placement”); and
- (b) the launch of a fully underwritten pro rata non-renounceable entitlement offer (“Rights Issue”) of 1 New Share for every 6.65 fully paid ordinary shares held as at 7.00pm (AEDT) on Thursday, 28 December 2023, by eligible shareholders with a registered address in Australia or New Zealand, or otherwise determined by the Company to be eligible to participate in the Rights Issue (“Eligible Shareholders”).

The issue price for each New Share under the Placement and the Rights Issue will be \$0.37.

Further details regarding the Rights Issue are set out in the ASX announcement relating to capital raising lodged with the ASX earlier today. An Offer Booklet for the Rights Issue is expected to be dispatched to Eligible Shareholders on Monday, 2 January 2024.

The Company confirms the following with respect to the Rights Issue:

- (a) the New Shares to be issued under the Rights Issue will be offered for issue without disclosure under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under Section 708AA(2)(f) of the Corporations Act as modified by ASIC;
- (c) as at the date of this notice the Company has complied with:
 - i. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - ii. sections 674 and 674A of the Corporations Act;
- (d) as at the date of this notice there is no excluded information (within the meaning of sections 708AA(8) and 708AA(9) of the Corporations Act); and

- (e) the potential effect of the issue of the New Shares under the Rights Issue will have on the control of Company, and the consequences of that effect, will depend on a number of factors, including investor demand and existing shareholdings. The potential effect and the consequences of that effect are assessed further below.

Further to paragraph (e) above and having regard to the composition of the Company's share register and the structure of the Rights Issue as a pro rata issue, the Rights Issue is not expected to have any material effect or consequences on the control of the Company.

The potential effect that the issue of the New Shares under the Rights Issue will have on the control of the Company and the consequences of that effect are as follows:

- given the structure of the Rights Issue as a pro rata offer, if all Eligible Shareholders take up their full entitlements under the Rights Issue, they will maintain their existing percentage interest in the total issued share capital of the Company in so far as the Rights Issue is concerned. However as set out above, in addition to the Rights Issue, the Company will undertake the Placement. The Placement will involve the issue of approximately an additional 21.5 million fully paid ordinary shares ("Placement Shares"). The Placement Shares will represent approximately 13.0% of the fully paid ordinary shares on issue in the Company following completion of the Placement. Accordingly, existing shareholders that do not participate in the Placement will be diluted as a result of the Placement;
- if Eligible Shareholders do not take up all of their entitlements in the Rights Issue, their holdings are likely to be diluted;
- the proportional interests of Shareholders who are ineligible shareholders will be diluted because those Shareholders are not entitled to participate in the Rights Issue; and
- the Rights Issue is fully underwritten by Bell Potter Securities Limited (ACN 006 390 772) and Taylor Collison Limited (ABN 53 008 172 450) ("Joint Underwriters") pursuant to an underwriting agreement between the Company and the Joint Underwriters. In the event there is a shortfall under the Rights Issue, those shortfall shares will be allocated to the Joint Underwriters and sub-underwriters. The issue of New Shares to the Joint Underwriters (or any sub-underwriters appointed by the Joint Underwriters) is not expected to have any material effect on the control of the Company.

– ENDS –

Authorisation and Additional Information

This announcement was authorised by the Board of Directors of Genetic Signatures Limited.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki
Managing Director and
Chief Executive Officer
john.melki@geneticsignatures.com
T: +61 (0)2 9870 7580

Karl Pechmann
Chief Financial and Operating Officer
and Company Secretary
karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures' proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen™* respiratory kits and the growing interest in its gastroenteritis products to further commercialise its **3base®** technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.